一龍馬/AI 情報站讀懂消息背後的脈絡
星期四
搜尋

Anthropic 表示,他們測試 Claude 是否能從零設計可與特定標的結合的全新蛋白質 binders,並由人類專家撰寫蛋白質設計提示

中文摘要

根據貼文,Claude 自主為 15 個標的中的 14 個設計出 protein binders,Anthropic 隨後與 Adaptyv Bio、Twist Bioscience 合作,獨立製作並測試這些蛋白質。貼文也交代了脈絡:傳統上,這類早期藥物開發步驟通常需要專家花數週到數月篩選大量候選分子;但來源未提供實驗成功率細節、結合強度數據、陰性結果或論文連結。

一龍馬判讀

若結果可重現,AI 可能把早期分子設計從單純輔助搜尋推向可產出實驗候選物,影響藥物研發團隊與合成生物公司。不過目前只有社群貼文摘要,缺少完整方法與數據,還不能等同於臨床或商業可用突破。

原文節錄

Anthropic · @AnthropicAI

Many drugs work by binding to a specific target in the body and blocking or changing what it does.…

取得全文 · 不代表內容已獨立查證

查看原文
完整收錄文字與來源

Many drugs work by binding to a specific target in the body and blocking or changing what it does. An important first step in the drug development process is designing a molecule that can bind tightly to its target. Traditionally, that's meant weeks or months of expert work per target, sifting through a large number of candidates to identify the few that work. We wanted to test if Claude could successfully design novel protein binders from scratch (also called de novo design). With a protein design prompt written by a human expert, Claude autonomously designed protein binders against 14 out of 15 targets. We then worked with Adaptyv Bio and Twist Bioscience, who independently built and tested the proteins Claude designed.

收錄日期
2026-08-20
來源
Nitter RSS(公開貼文)
抓取時間
2026/08/20 06:12(台北)